Publikationen

2010

Recurrence Free Survival in Prostate Cancer is Related to Increased Stromal TRAIL Expression - (submitted). Anees, M., Horak, P., El-Gazzar, A., Susani, M., Heinze, G., Perco,P., Pangerl, T., Loda, M., Lis, R., Krainer, M. and Oh, W.K. (2010)

Silencing of N33 (TUSC3) Independently Predicts Ovarian Cancer Outcome by Modifying Cellular N-glycosylation Patterns - (submitted). Pils, D., Horak, P., Petz, M., Alfanz, A., Gugerell, A., Wittinger, M., Gregor, W., Gleiss, A., Kirisits, A.,  Omann, M., Tong, D., Zeillinger, R., Braicu, El., Sehouli, J. and Krainer, M. (2010)

HCRP1 as Regulator of ERBB Receptor Trafficking is a Potential Biomarker for EGFR-Driven Tumors - (submitted). Wittinger, M., El-Gazzar, A., Pils, D., Grunt, TW., Sibilia, M., Horvat, R., Schemper, M., Zeillinger, R., Schöfer, C. and Krainer, M. (2010)

Natural immunity enhances the activiti of a DR5 agonistic antibody and carboplatin in the treatment of ovarian cancer - Mol Cancer Ther. - 9(4):1007-18. El-Gazzar, A., Perco, P., Eckelhart, E., Anees, M., Sexl V., Mayer, B., Liu Y., Mikulits, W., Horvat, R., Pangerl, T., Zheng, D., Krainer, M. (2010)

The role of c-FLIP(L) in ovarian cancer: chaperoning tumor cells from immunosurveillance and increasing their invasive potential. - Gynecol Oncol. - 117(3):451-9. El-Gazzar, A., Wittinger, M., Perco, P., Annes, M., Horvat, R., Mikulits, M., Grunt, TW., Mayer, B. and Krainer, M. (2010)

BAMBI is overexpressed in ovarian cancer and co-translocates with Smads into the nucleus upon TGF-ß treatment. - Gynecol Oncol. - 117(2):189-97. Pils, D., Wittinger, M., Petz, M., Gugerell, A., Gregor, W., Alfanz, A., Horvat, R., Braicu, EI., Sehouli, J., Zeillinger, R., Mikulits, W. and Krainer M. (2010)

BOOK CHAPTERS M. Krainer
Molekulargenetische Grundlagen häufiger Krebserkrankungen: Basis für Früherkennung und neue therapeutische Ansätze - Genetic Screening, Herausgeber: Michael Fischer und Markus Hengstschläger, Peter Lang Internationaler Verlag der Wissenschaften, Frankfurt am Main 2010.

 2009

Third consensus on medical treatment of metastatic breast cancer - Ann Oncol. - (11):1771-85. Beslija, S., Bonneterre, J., Burstein, HJ., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Köstler, WJ., Krainer, M., Menard, S., Petit, T., Petrzelka, L., Possinger, K., Schmid, P., Stadtmauer, E., Stockler, M., Van Belle, S., Vogel, C., Wilcken, N., Wiltschke, C., Zielinski, CC., Zwierzina, H.; for the Central European Cooperative Oncology Group CECOG), (2009)

2008

Chemotherapy for prostate cancer - Wien Klin Wochenschr. - 120(13-14):440-9. Rauchenwald, M., De Santis, M., Fink, E., Höltl, W., Kramer, G., Marei, IC., Neumann, HJ., Reissigl, A., Schmeller, N., Stackl, W., Hobisch, A., Krainer, M. (2008)

Linking the ovarian cancer transcriptome and immunome. - BMC Syst Biol. - 3;2:2. Rapberger, R., Perco, P., Sax, C., Pangerl, T., Siehs, C., Pils, D., Bernthaler, A., Lukas, A., Mayer, B., Krainer, M. (2008)

Targeting signaling pathways in ovarian cancer. - Expert Opinion on Therapeutic Targets - 12(3):353-365. Reibenwein, J., Krainer, M. (2008)

2007

Oncogenic BARD1 isoforms expressed in gynecological cancers. - Cancer Research - 67(24):11876-85. Li, L., Ryser, S., Dizin, E., Pils, D., Krainer, M., Jefford, Ch.E., Bertoni, F., Zeillinger, R. and Irminger-Finger, I. (2007)

EGFR Degradation and Cancer: Oncogenic Signalling from a different perspective. - Int J Biochem Cell Biol. - 39(12):2173-82. Kirisits, A., Pils, D., Krainer, M. (2007)

A Prospective, Open Label, Randomized Phase II Trial of Weekly Docetaxel Versus Weekly Vinorelbine as First Line Chemotherapy in Patients With Androgen Independent Prostate Cancer. - J Urol. - (Vol. 177, Issue 6, Pages 2141-2145). Krainer, M., Tomek, S., Elandt, K., Horak, P., Albrecht, W., Eisenmenger, M., Höltl, W., Schramek, P., Stackl, W., Zielinski, C., Reibenwein, J. (2007)

In ovarian cancer the prognostic influence of Her2/neu is independent from the CXCR4/SDF-1 signalling pathway. - Br J Cancer - 96(3):485-91. Pils, D., Pinter, A., Reibenwein, J., Alfanz, A., Horak, P., Schmid, B., Hefler, L., Horvat, R., Reinthaller, A., Zeillinger, R., Krainer, M. (2007)

Promoter Hyermethylation of GSTP1, AR, and 14-3-3σ in Serum of Prostate Cancer Patients and its clinical relevance. - The Prostate - 67(4):427-32. Reibenwein, J., Pils, D., Horak, P., Tomicek, B., Goldner, G., Worel, N., Elandt, K., Krainer, M. (2007)

The medical management of prostate cancer: a multidisciplinary team approach. BJU Int. - 99(1):22-7. Sternberg, C., Krainer, M., Oh, W., Bracarda, S., Bellmunt, J., Ozen, H., Zlotta, A., Beer,T., Oudard, S., Rauchenwald, M., Skoneczna, I., Borner, M., Fitzpatrick, J. (2007)

2006

Second consensus on medical treatment of metastatic breast cancer. - Ann Oncol. - 18(2):215-225. Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Goodwin, P., Heinemann, V., Jassem, J., Kostler, WJ., Krainer, M., Menard, S., Petit, T., Petruzelka, L., Possinger, K., Schmid, P., Stadtmauer, E., Stockler, M., Van Belle, S., Vogel, C., Wilcken, N., Wiltschke, C., Zielinski, C., Zwierzina, H. (2006)

2005

Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: a single-institution experience. - Anticancer Drugs - 16(2):185-90. Kostler, WJ., Steger, GG., Krainer, M., Kornek, GV., Locker, GJ., Brodowicz, T., Marosi, C., Singer, CF., Hudelist, G., Rabitsch, W., Wiltschke, C., Zielinski, C. (2005)

Perturbation of the TRAIL cascade in ovarian cancer: Overexpression of FLIPL and deregulation of the functional TRAIL receptors DR4 and DR5. - Clinical Cancer Research - 11-8585-91. Horak, P., Pils, D., Pinter, A., Kaider, A., Elandt, K., Sax, C., Zielinski, C., Horvat, R., Zeillinger, R., Reinthaller, A., Krainer, M. (2005)

Five genes from chromosome 8p are significantly downregulated in ovarian cancer: N33 and EFA6R have a potential impact on overall survival. - Cancer - 104(11):2417-29. Pils, D., Horak, P., Gleiss, A., Sax, C., Fabjani, G., Möbus, V.J., Reinthaller, A., Zeillinger, R., Zielinski, C., Krainer, M. (2005)

Contribution of epigenetic silencing of TNF-related apoptosis inducing ligand (TRAIL) receptor 1 (DR4) to TRAIL resistance and ovarian cancer. - Molecular Cancer Research - (6):335-43. Horak, P., Pils, D., Haller, G., Pribill, I., Roessler, M., Tomek, S., Horvat, R., Zeillinger, R., Zielinski, C., Krainer, M. (2005)

Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer. - Gynecologic Oncology - 97: 514-518. Horak, P., Pils, D., Roessler, M., Tomek, S., Elandt, K., Zeillinger, R., Zielinski, C., Krainer, M. (2005)

2004

Single agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: A single institution experience - Anticancer Drugs - 24 (2C): 1127-30. Köstler, W.J., Steger, G.G., Krainer, M., Kornek, G.V., Locker, G.J., Brodowicz, T., Marosi, C., Singer, C.F., Hudelist, G., Rabitsch, W., Wiltschke, Zielinski, C. (2004)

Resistance to Trail-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. - Gynecol Oncol - 94: 107-114. Tomek, S., Horak, P., Pribill, I., Haller, G., Rössler, M., Zielinski, C., Pils, D., Krainer, M. (2004)

Monitoring of Serum Her-2/neu Predicts Histopathologic Response to Neoadjuvant Trastuzumab-based Therapy for Breast Cancer - Anticancer Research - 24: 1127-1130. Koestler, W.J., Steger, G.G., Soleiman, A., Schwab, B., Singer, C.F., Tomek, S., Brodowicz, T., Krainer, M., Wiltschke, C., Horvat, R., Jakesz, R., Zielinski, C.C. (2004)

Monitoring of Serum Her-2/neu predicts Response and Progression-free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer. - Clin Cancer Research - Clin Cancer Res - 10(5):1618-24 Koestler, W., Schwab, B., Singer, C., Neumann, R., Rücklinger, T., Brodowicz, T., Tomek, S., Niedermayr, M., Hejna, M., Steger, G.G., Krainer, M., Wiltschke, C., Zielinski, C.C (2004)

2003

Cytotoxic Chemotherapy in Breast Cancer: Efficacy of Combination Therapy vs. Monotherapy. - Breast Cancer Res Tre - 81: 13-17. Krainer, M. and Zielinski, C.C. coordinators (2003) Consensus on medical treatment of breast cancer - Breast Cancer Res Tre - 81: 1-7.

Rad 52 gene mutations in breast/ovarian cancer families and sporadic ovarian carcinoma patients. - Oncol Rep - 10 (5): 15551-3. Tong, D., Volm, T., Eberhardt, E., Krainer, M., Leodolter, S., Kreienberg, R., Zeillinger, R. (2003)

Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines. - Eur J Cancer -39(9): 1318-29. Tomek, S., Koestler, W., Horak, P., Grunt, T., Brodowicz, T., Pribill, I., Halaschek, J., Haller, G., Wiltschke, C., Zielinski, C.C., Krainer, M. (2003)

2002

Technetium-99m-tetrofosmin scintigraphy in patients with metastatic soft tissue sarcoma. - Oncol Rep - 9, - 1009-13. Karanikas,G., Koestler, W.J., Becherer, A., Wiesner, K., Dudczak, R., Krainer, M., Kletter, K. (2002)